Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24974368 | 0.78 | PKM (0.47) | — | |
| SCHEMBL21152067 | 0.76 | POLB (0.47) | USP2POLBSMN1; SMN2TSHRALDH1A1 | |
| SCHEMBL24974541 | 0.71 | ALDH1A1 (0.52) | USP2POLBSMN1; SMN2TSHRALDH1A1 | |
| SCHEMBL24974592 | 0.70 | ALDH1A1 (0.46) | USP2POLBSMN1; SMN2TSHRALDH1A1 | |
| SCHEMBL6271377 | 0.69 | ALDH1A1 (0.57) | USP2TSHRALDH1A1MAPTMEN1 | |
| SCHEMBL5843005 | 0.69 | ALDH1A1 (0.49) | USP2POLBSMN1; SMN2NPSR1ALDH1A1 | |
| SCHEMBL5842938 | 0.68 | ALDH1A1 (0.51) | USP2POLBSMN1; SMN2NPSR1ALDH1A1 | |
| SCHEMBL5842398 | 0.68 | MAPT (0.54) | USP2POLBSMN1; SMN2NPSR1TSHR | |
| SCHEMBL6265568 | 0.68 | MAPT (0.56) | USP2POLBTSHRALDH1A1MAPT | |
| SCHEMBL5841187 | 0.68 | SMN1; SMN2 (0.59) | USP2SMN1; SMN2NPSR1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11572370-B2 | CD16A binding agents and uses thereof | BIOHAVEN THERAPEUTICS LTD. (US) | 2023-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11572370-B2 | CD16A binding agents and uses thereof | FCGR1A, FCGR2A, FCGR3B | USP2 4864/4885POLB 4058/4885SMN1; SMN2 3020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.